Recent News

• 09.08.2025 - BioAtla Announces Regulatory Update on Clinical Development Plan for Ozuriftamab Vedotin in Oropharyngeal Squamous Cell Carcinoma (OPSCC) Following Productive Type B (End of Phase 2) Meeting with FDA
• 09.08.2025 - BioAtla Announces Regulatory Update on Clinical Development Plan for Ozuriftamab Vedotin in Oropharyngeal Squamous Cell Carcinoma (OPSCC) Following Productive Type B (End of Phase 2) Meeting with FDA
• 08.07.2025 - BioAtla Second Quarter 2025 Financial Results and Business Highlights Conference Call
• 08.07.2025 - BioAtla Second Quarter 2025 Financial Results and Business Highlights Conference Call
• 08.07.2025 - BioAtla Reports Second Quarter 2025 Financial Results and Highlights Recent Progress
• 08.07.2025 - BioAtla Reports Second Quarter 2025 Financial Results and Highlights Recent Progress
• 08.04.2025 - BioAtla to Announce Second Quarter 2025 Financial Results and Provide Business Highlights on August 7, 2025
• 08.04.2025 - BioAtla to Announce Second Quarter 2025 Financial Results and Provide Business Highlights on August 7, 2025
• 07.17.2025 - BioAtla Announces Upcoming Oral Presentation at the 2025 European Society for Medical Oncology (ESMO) TAT Asia Meeting
• 07.17.2025 - BioAtla Announces Upcoming Oral Presentation at the 2025 European Society for Medical Oncology (ESMO) TAT Asia Meeting

Recent Filings

• 09.02.2025 - 4 Statement of changes in beneficial ownership of securities
• 09.02.2025 - 4 Statement of changes in beneficial ownership of securities
• 09.02.2025 - 4 Statement of changes in beneficial ownership of securities
• 09.02.2025 - 4 Statement of changes in beneficial ownership of securities
• 08.07.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 08.07.2025 - EX-99.1 EX-99.1
• 08.07.2025 - 8-K Current report
• 06.20.2025 - 8-K Current report